Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges
- 612 Downloads
Despite the great success of anti-tumour necrosis factor-based therapies, the treatment of Crohn’s disease (CD) and ulcerative colitis (UC) still remains a challenge for clinicians, as these drugs are not effective in all patients, their efficacy may wane with time, and their use can increase the risk of adverse events and be associated with the development of new immune-mediated diseases. Therefore, new therapeutic targets are currently being investigated both in pre-clinical studies and in clinical trials. Among the technologies used to build new therapeutic compounds, the antisense oligonucleotide (ASO) approach is slowly gaining space in the field of inflammatory bowel diseases (IBDs), and three ASOs have been investigated in clinical trials. Systemic administration of alicaforsen targeting intercellular adhesion molecule-1, a protein involved in the recruitment of leukocytes to inflamed intestine, was not effective in CD, even though the same compound was of benefit when given as an enema to UC patients. DIMS0150, targeting nuclear factor (NF) κB-p65, a transcription factor that promotes pro-inflammatory responses, was very promising in pre-clinical studies and is currently being tested in clinical trials. Oral mongersen, targeting Smad7, an intracellular protein that inhibits transforming growth factor (TGF)-β1 activity, was safe and well tolerated by CD patients, and the results of a phase II clinical trial showed the efficacy of the drug in inducing clinical remission in patients with active disease. In this leading article, we review the rationale and the clinical data available regarding these three agents, and we discuss the challenge of using ASOs in IBD.
Declaration of personal interests
GM has filed a patent related to the treatment of IBD with Smad7 ASOs. The remaining authors have no conflicts of interest.
No funding was used to support the writing of this manuscript.
- 19.Yu B, Mao Y, Bai LY, Herman SE, Wang X, Ramanunni A, et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood. 2013;121(1):136–47. doi:10.1182/blood-2012-01-407742.CrossRefPubMedCentralPubMedGoogle Scholar
- 20.Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006;24(9):1428–34. doi:10.1200/JCO.2005.04.3299.CrossRefPubMedGoogle Scholar
- 21.Stein CA, Wu S, Voskresenskiy AM, Zhou JF, Shin J, Miller P, et al. G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Clin Cancer Res. 2009;15(8):2797–807. doi:10.1158/1078-0432.CCR-08-2610.CrossRefPubMedCentralPubMedGoogle Scholar
- 27.Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). JPharmacol Exp Ther. 1997;282(3):1173–80.Google Scholar
- 30.Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut. 2002;51(1):30–6.CrossRefPubMedCentralPubMedGoogle Scholar
- 32.van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23(10):1415–25. doi:10.1111/j.1365-2036.2006.02910.x.CrossRefPubMedGoogle Scholar
- 33.Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23(10):1403–13. doi:10.1111/j.1365-2036.2006.02837.x.CrossRefPubMedGoogle Scholar
- 34.Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006;23(10):1427–34. doi:10.1111/j.1365-2036.2006.02909.x.CrossRefPubMedGoogle Scholar
- 36.Vegter S, Tolley K, Wilson Waterworth T, Jones T, Jones H, Jewell D. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2013;38(3):284–93. doi:10.1111/apt.12369.CrossRefPubMedGoogle Scholar
- 40.Murano M, Maemura K, Hirata I, Toshina K, Nishikawa T, Hamamoto N, et al. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 2000;120(1):51–8.CrossRefPubMedCentralPubMedGoogle Scholar
- 43.Tahara K, Samura S, Tsuji K, Yamamoto H, Tsukada Y, Bando Y, et al. Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(d, l-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials. 2011;32(3):870–8. doi:10.1016/j.biomaterials.2010.09.034.CrossRefPubMedGoogle Scholar
- 47.Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, Strober W. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med. 2000;192(1):41–52.CrossRefPubMedCentralPubMedGoogle Scholar
- 53.Zorzi F, Calabrese E, Monteleone I, Fantini M, Onali S, Biancone L, et al. A phase 1 open-label trial shows that Smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Aliment Pharmacol Ther. 2012;36(9):850–7. doi:10.1111/apt.12051.PubMedGoogle Scholar